1-3 of 3
Jose-Mario Capo-Chichi
Close
Sort by
Journal Articles

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

Maria Agustina Perusini, Daniela Žáčková, Taehyung Kim, Katia Pagnano, Carolina Pavlovsky, Ivana Ježíšková, Anežka Kvetková, Tomáš Jurček, Jaeyoon Kim, Youngseok Yoo, Seongyoon Yi, Hyewon Lee, Kyoung Ha Kim, Myunghee Chang, Jose-Mario Capo-Chichi, Jessie J. F. Medeiros, Andrea Arruda, Mark Minden, Zhaolei Zhang, Sagi Abelson, Jiri Mayer, Dennis Dong Hwan Kim
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2361–2372.
https://doi.org/10.1182/bloodadvances.2023012127
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN

Marta B. Davidson, James A. Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi, Wei Xu, Verna Cheung, Andrea Arruda, Aniket Bankar, Guillaume Richard-Carpentier, Steven Chan, Dawn Maze, Mark D. Minden, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Anne Tierens, Auro Viswabandya, Vikas Gupta
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1281–1294.
https://doi.org/10.1182/bloodadvances.2023011735
Published: 2024
Includes: Supplemental data
Journal Articles

Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL –negative MPN in blast phase

Clinical Trials & Observations
Vikas Gupta, James A. Kennedy, Jose-Mario Capo-Chichi, Soyoung Kim, Zhen-Huan Hu, Edwin P. Alyea, Uday R. Popat, Ronald M. Sobecks, Bart L. Scott, Aaron T. Gerds, Rachel B. Salit, H. Joachim Deeg, Ryotara Nakamura, Wael Saber
Journal: Blood Advances
Blood Adv (2020) 4 (21): 5562–5573.
https://doi.org/10.1182/bloodadvances.2020002727
Published: 2020
Includes: Supplemental data